RenalytixAI to Collaborate with AstraZeneca to Improve Outcomes for Patients with Chronic Disease
Parties to adopt multi-phase approach to develop precision medicine strategies to optimize treatment of cardiovascular, renal and metabolic disease
NEW YORK, Aug. 21, 2020 (GLOBE NEWSWIRE) --?Renalytix AI plc?(LSE: RENX) (NASDAQ: RNLX), ?today announced a collaboration with AstraZeneca (LSE/STO/NYSE: AZN) to develop and launch precision medicine strategies for cardiovascular, renal and metabolic diseases. The first stage in the collaboration will use KidneyIntelX, an artificial intelligence-enabled?in vitro?diagnostic platform, to examine further improving outcomes for patients with chronic kidney disease (CKD) and its complications, in coordination with the Mount Sinai Health System. The goal of the first stage is to help improve guideline-based standard-of-care for optimal utilization of existing and novel therapeutics using the KidneyIntelX testing platform and proprietary care management software.
An estimated 700 million patients worldwide have CKD,1?which is also associated with an increased risk of metabolic and hematologic complications, such as hyperkalemia (elevated levels of potassium in the blood) and anemia.2,3 The first stage will assess the impact of AI-enabled?in vitro?diagnostic solutions to optimize utilization of therapeutics in CKD under current standard of care protocols. Based on study outcomes, a multi-center, randomized controlled trial will be initiated to evaluate uptake and adherence to new potassium-binding agents in patients with CKD and hyperkalemia. The studies will be conducted in coordination with the Mount Sinai Health System, where KidneyIntelX testing and care management software are currently being deployed for commercial clinical use. ?We believe this collaboration will define how we can leverage KidneyIntelX to improve the care and outcomes for patients affected by chronic diseases, such as kidney disease, diabetes, and cardiovascular disease,? said Barbara Murphy, MD, Chair of the Samuel Bronfman Department of Medicine, Dean for Clinical Integration and Population Health Management at the Icahn School of Medicine at Mount Sinai, and board member of RenalytixAI. ?By using a more personalized approach, our initial goal is to help realize improved outcomes for more than 240,000 patients with chronic kidney disease within the Mount Sinai Health System.? RenalytixAI and AstraZeneca will use KidneyIntelX with the aim to:- Help improve physician uptake and patient adherence to existing potassium-binding therapeutics and other approved products in CKD through early identification of previously hidden high-risk patient groups
- Accelerate patient identification and recruitment for clinical trials
- Complement commercialization efforts with outcomes from KidneyIntelX results
Walbrook PR?Limited | ||
Paul McManus / Lianne Cawthorne | ||
Tel: 020 7933 8780 or?renalytix@walbrookpr.com Mob: 07980 541 893 / 07584 391 303 |
- Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990?2017: asystematic analysis for the Global Burden of Disease Study 2017.The?Lancet.?2018; 392:1789?858. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)32279-7/fulltext#seccestitle10. Published November 10, 2018. Accessed August 4, 2020.
- National Kidney Foundation. Clinical Update on Hyperkalemia. 2016. https://www.kidney.org/sites/default/files/02-10-7260%20Clinical%20Bulletin.pdf
- National Institute of Diabetes and Digestive and Kidney Disease. Anemia in Chronic Kidney Disease. ?https://www.niddk.nih.gov/health-information/kidney-disease/anemia#:~:text=What%20causes%20anemia%20in%20chronic,of%20the%20oxygen%20it%20needs. Published November 8, 2014. Accessed August 4, 2020.
- Desai NR, Reed P, Alvarez PJ, et al. The Economic Implications of Hyperkalemia in a Medicaid Managed Care Population. American Health & Drug Benefits. 2019.12(7)352-361.http://www.ahdbonline.com/issues/2019/november-2019-vol-12-no-7/2862-the-economic-implications-of-hyperkalemia-in-a-medicaid-managed-care-population. Accessed August 4, 2020.
- Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease.?Kidney International Supplement?2013; (3):1?150. Accessed August 4, 2020.
- Centers for Disease Control and Prevention. Chronic Kidney Disease in the United States, 2019. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention; 2019.?Accessed August 4, 2020.
- A Hidden Epidemic: More than 850 Million Suffer from Kidney Diseases Worldwide, Organizations Report. ASN Kidney News. https://www.kidneynews.org/kidneynews/10_8/4/4.pdf. Published August 2018. Accessed August 4, 2020.
- National Institute of Diabetes and Digestive and Kidney Disease. Kidney Disease Statistics for the United States.?https://www.niddk.nih.gov/health-information/health-statistics/kidney-disease. Updated 2020. ?Accessed August 4, 2020.
- Thorp M, Johnson S, Yang X, et al. Effect of anaemia on mortality, cardiovascular hospitalizations and end-stage renal disease among patients with chronic kidney disease.?APSN. 2009;14(2):240-246. doi:10.1111/j.1440-1797.2008.01065.x.
Intraday | 3 Month | 6 Month | 1 Year |
Quote delayed at least 20 mins. |